The disclosure provides for a pharmaceutical composition and method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic has normal or substantially normal biliary tract function or has non or early stage hepatocyte apoptosis and administering a therapeutically effective amount of a pharmaceutical composition comprising EPAs.本揭示內容提供用以治療有需要個體之脂肪肝疾病或病症的醫藥組合物及方法,該方法包含選擇患有或疑似患有脂肪肝疾病或病症之個體,其中該個體係無糖尿病、糖尿病前期、輕度糖尿病;具有正常或實質上正常的膽道功能;或無肝細胞凋亡或具有早期肝細胞凋亡;及投與治療有效量之包含FPA之醫藥組合物。
